
Natera Inc (AKA: GSN~Gene Security Network) Profile last edited on: 6/4/2024
CAGE: 48FG5
UEI: C3ZKLH9BHYC1
Business Identifier: Cell-free DNA testing to elevate the science and utility of prenatal testing. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
13011 Mccallen Pass Building A Suite 100
San Carlos, CA 78753
San Carlos, CA 78753
(650) 249-9090 |
info@natera.com |
www.natera.com |
Location: Multiple
Congr. District: 15
County: Travis
Congr. District: 15
County: Travis
Public Profile
Previously doing business as Gene Security Network, Natera, Inc. is a genetic testing company designing targeted assays to analyze tiny quantities of DNA: elevating the science and utility of prenatal testing. Fairly SBIR active in the arly years, but now longtime having outgrown SBIR eligibility, the defined mission of the company is to help families diagnose and manage genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California, currently offering a host of preconception and prenatal genetic testing services primarily to OBGYN physicians and in-vitro fertilization centers. In 2013, the company launched Panorama, a safe, simple test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Tests developed by Natera have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Natera was honored in 2014 to be selected to attend and participate in the famous, highly exclusive Davos World Economic Forum.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
500+Revenue Range
Over 50MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : NTRAIP Holdings
250-500Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2012 | 2 | NIH | $1,803,657 | |
Project Title: Non-Invasive Aneuploidy Screening Of Circulating Fetal Cells For Prenatal Diagnos | ||||
2010 | 2 | NIH | $1,799,814 | |
Project Title: Array Informatics To Understand Ploidy Concordance | ||||
2009 | 2 | NIH | $1,689,902 | |
Project Title: Phase I Application: Cleaning of Single Cell DNA Measurements In-Silico | ||||
2006 | 1 | NIH | $178,940 | |
Project Title: Novel Statistical Methods for Improving the Prediction of HIV-1 Response to ART a | ||||
2006 | 1 | NIH | $218,859 | |
Project Title: Integrating, Validating & Applying Pharmacogenetic Data |
Key People / Management
Matthew Rabinowitz -- President and Chief Executive Officer
Steve Chapman -- Vice President of Commercial Operations
Matthew Hill -- Vice President, Research
Dave Johnson -- Director of Research and Development
Jennifer Keller -- Vice President, Clinical Affairs and Medical Education
Solomon Moshkevich -- Vice President of Marketing and Business Development
Dan Potter -- Laboratory Director
Jonathan Sheena -- Chief Technology Officer. Founder
Asim Siddiqui -- Vice President, Product Development
Styrmir Sigurjonsson -- Director of Statistics
Joshua Sweetkind-Singer -- Director of Statistics
Steve Chapman -- Vice President of Commercial Operations
Matthew Hill -- Vice President, Research
Dave Johnson -- Director of Research and Development
Jennifer Keller -- Vice President, Clinical Affairs and Medical Education
Solomon Moshkevich -- Vice President of Marketing and Business Development
Dan Potter -- Laboratory Director
Jonathan Sheena -- Chief Technology Officer. Founder
Asim Siddiqui -- Vice President, Product Development
Styrmir Sigurjonsson -- Director of Statistics
Joshua Sweetkind-Singer -- Director of Statistics